Does Enasidenib have a long-lasting effect on AML?

Enasidenib is a selective IDH2 inhibitor, mainly used to treat relapsed or refractory acute myeloid leukemia (AML) carrying specific IDH2 gene mutations. The original intention of developing this type of drug is to target the molecular drivers of AML, by blocking the production of the abnormal metabolite 2-hydroxyglutarate (2-HG), restoring the differentiation of leukemia cells, and thus achieving the purpose of inhibiting tumor development. Unlike traditional chemotherapy, ensidipine does not work by directly killing cancer cells, but by reversing differentiation block and restoring leukemia cells to their normal maturation path, so its efficacy is more durable and stable.

From a clinical practice perspective, ensidipine can bring about sustained remission in some patients, and some patients can even maintain disease control for a longer period of time. This advantage of long-lasting efficacy is closely related to its unique mechanism of action. Because it changes the biological behavior of leukemia cells through correction at the molecular level, it not only reduces the tumor load, but also delays the risk of disease recurrence. Although individual differences still exist, ensidipine has become a valuable precision treatment option for patients with positive IDH2 mutations.

Of course, drug resistance or reduced efficacy may still occur during long-term treatment. This is often associated with tumor cells acquiring new mutations or activating alternative signaling pathways. Some patients may develop adverse reactions such as differentiation syndrome after using it for a period of time, which requires close monitoring and intervention by a doctor. Overall, the efficacy of ensidipine shows a certain persistence in many patients, but it still needs to be combined with follow-up and molecular testing to ensure timely adjustment of treatment plans when the disease dynamics change. As more research data accumulates, combination use with other drugs may be explored in the future to further prolong the durability of the efficacy and provide AML patients with a more stable survival benefit.

Reference materials:https://www.idhifa.com/